Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Prof Kevin Mackway-Jones
+44 (0)1612 766781
kevin.c.mackway-jones@manchester.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Anticoagulation of Calf Thrombosis (ACT): A Pilot Feasibility Study
Back

Anticoagulation of Calf Thrombosis (ACT): A Pilot Feasibility Study

Not Recruiting

Open to: All Genders

Age: Adult

Manchester

Medical Conditions

Calf thrombosis/below knee DVT

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Not provided at time of registration

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

01 Jan 2011 01 Aug 2012

Publications

2012 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/22472294 protocol2014 Results article in http://www.ncbi.nlm.nih.gov/pubmed/25010443 results

Interventional

Intervention Type : Other
Intervention Description : Patients will be randomised to one of the following treatment groups1. Group A: conservative treatment (TED stockings and simple analgaesia) and full-dose anticoagulation, initiated with Low Molecular Weight Heparin (LMWH) (dalteparin, dosage based on weight) then converted to oral anticoagulation with warfarin for a duration of 3 months total. Warfarin dosing to be based on International Normalized Ratio (INR) blood clotting measurements aiming for a target range of 2-3. 2. Group B: conservative treatment only

All patients will have vascular ultrasound scans at 7 days and 21 days to look for propagation or clot development, along with clinical review. All patients will be clinically followed for the three month duration of treatment. All patients will also be reviewed at two years regarding assessment for post-thrombotic leg syndrome.




You can take part if:



You may not be able to take part if:


1. Hospitalised patients2. Patients on long-term anticoagulation3. Associated proximal DVT or confirmed PE4. Contraindication to anticoagulation (active bleeding, recent haemorrhagic CVA or upper GI bleed)5. Other indication for immediate warfarinisation as per BSH guidelines: Prior confirmed and treated above knee DVT/PE, antiphospholipid syndrome, symptomatic inherited thrombophilia6. Pregnancy7. Chronic non propagating thrombus seen on prior USS8. Previous enrolment to the ACT study and achievement of the primary outcome


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Emergency Department
    Manchester
    M13 9WL

This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.

Prof Kevin Mackway-Jones
+44 (0)1612 766781
kevin.c.mackway-jones@manchester.ac.uk



The study is sponsored by Central Manchester NHS Foundation Trust (UK) and funded by College of Emergency Medicine (UK).



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN75175695
Last updated 14 July 2014

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top